BBIO vs. TEVA: BridgeBio Pharma vs. Teva Pharmaceutical Stock Comparison

Company Profile

BridgeBio Pharma (BBIO) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BBIO is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

BridgeBio Pharma (BBIO) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Teva Pharmaceutical (TEVA) earns 6.65% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Teva Pharmaceutical (TEVA) reports 2.94%, ranking against industry peers normally.

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Teva Pharmaceutical (TEVA) reports 27.40%, ranking against industry peers normally.

Profitability Metrics

Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Teva Pharmaceutical (TEVA) at 4.31% is closer to the peer norm — faster top-line expansion for BBIO.

Neither BridgeBio Pharma (BBIO) nor Teva Pharmaceutical (TEVA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both BridgeBio Pharma (BBIO) at 2.09 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Only one side’s leverage can be read here: Teva Pharmaceutical (TEVA) carries debt-to-equity ratio of 2.13 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither BridgeBio Pharma (BBIO) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BridgeBio Pharma (BBIO) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Teva Pharmaceutical (TEVA) trades at 99.09 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while BridgeBio Pharma (BBIO) at 15.31 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Teva Pharmaceutical (TEVA) reports 6.23, ranking against industry peers normally.

Valuation Metrics